Risk factors for early morbidity and mortality of HIV-exposed uninfected infants
Risk factors for early morbidity and mortality of HIV-exposed uninfected infants
批准号:
9086206
负责人:
Scott Dryden-Peterson
金额:
$12.77万
依托单位国家:
美国
项目类别:
财政年份:
2012
资助国家:
美国
项目状态:
已结题
起止时间:
2012-07-05 至 2017-09-30
关键词:
2 year oldAccountingAcquired Immunodeficiency SyndromeAddressAffectAgeAnemiaAntibodiesBiological FactorsBirthBotswanaBreast FeedingCD4 Lymphocyte CountCellsCessation of lifeChildChild MortalityClinical DataCountryDataDevelopmentDevelopment PlansDiseaseEconomicsEpidemicEquilibriumEtiologyExcess MortalityFoodGoalsGuidelinesHIVHIV-exposed uninfected infantHealthHighly Active Antiretroviral TherapyHospitalizationHouseholdHumoral ImmunitiesImmunoglobulin GInfantInfant MortalityInfectionInstitutesInterventionKnowledgeL CellsLinkLow Birth Weight InfantMediatingMentorsMeta-AnalysisMorbidity - disease rateMother-to-child HIV transmissionMothersNewborn InfantOutcomePatternPreventionPublic HealthResearchResearch PersonnelResourcesRiskRisk FactorsSpecimenStagingTimeVertical Disease TransmissionViral Load resultWomanWorkZidovudineadverse outcomeantiretroviral therapycareer developmentclinically significantcohortexperiencefeedinghigh riskimprovedimproved outcomeinfant outcomemortalitypathogenplacental transferpregnantprematurepreventprogramsskillssocialtransmission processvaccination strategy
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Over two million children are born to HIV-infected women annually. With advances in access to antiretroviral therapy and strategies to prevent mother-to-child transmission (MTCT), infant infection has become uncommon in settings like Botswana. However, these HIV-exposed but uninfected infants remain at 2 to 4-fold greater risk of dying than matched HIV-unexposed children, accounting for more than half of all deaths before age 5 in Botswana. Despite its great public health importance, the etiology of this mortality gap is unknown and strategies to mitigate this excess mortality in HIV-exposed uninfected (HIV-EU) infants have not been previously studied. Advanced maternal HIV disease is associated with decreased transfer of protective antibodies and poor infant outcomes. Treatment of maternal HIV, through expanded use of maternal highly- active antiretroviral therapy (HAART) for prevention of MTCT, as endorsed by recently revised WHO guidelines, may also improve health outcomes of uninfected infants. However, maternal HAART is associated with increased risk of prematurity, low birth weight, and severe infant anemia- all important predictors of increased mortality. Utilizing unique clinical data and specimens from well-characterized cohorts at the Botswana Harvard AIDS Institute Partnership, the project will examine the critical question of the effect of maternal HAART and other factors on the overall health of HIV-EU infants. The project as two specific aims: 1) determine factors associated with death or hospitalization (including HAART) among 2621 HIV-EU infants in Botswana by pooling data from 4 large cohorts, and 2) determine if reduced infant antibody levels to common pathogens are associated with lack of maternal HAART, and with death or hospitalization in HIV-EU infants. The results of these studies could impact the use of maternal HAART, vaccination strategy, and other interventions to improve outcomes for the rising number of HIV-exposed, uninfected infants. In addition, these mentored projects are part of a detailed Career Development Plan that will provide the Candidate with the knowledge, skills, and experience to successfully transition to an independent investigator.
期刊论文(4)
专著(0)
科研奖励(0)
会议论文
A retrospective review of patients with Kaposi's sarcoma in Botswana.
对博茨瓦纳卡波西肉瘤患者的回顾性评价。
DOI:
10.1111/ijd.14305
发表时间:
2019
期刊:
International journal of dermatology
影响因子:
3.6
作者:
[Slaught,Christa, Williams,Victoria, Grover,Surbhi, Bigger,Elizabeth, Kayembe,Mukendi, Chiyapo,Sebathu, Jackson,NicholasJ, Dryden-Peterson,Scott, Kovarik,CarrieL, Wanat,KarolynA]
通讯作者:
Wanat,KarolynA
Botswana CASCADE Clinical Trials Site
-
批准号:10544424
-
项目类别:
-
资助金额:$25.78万
-
财政年份:2022
-
负责人:Scott Dryden-Peterson
-
依托单位:
A multilevel intervention (Potlako+) to improve timely cancer detection and treatment initiation
-
批准号:10020924
-
项目类别:
-
资助金额:$47.84万
-
财政年份:2019
-
负责人:Scott Dryden-Peterson
-
依托单位:
Covid-19-related cervical cancer treatment interruption and role of neoadjuvant chemotherapy
-
批准号:10381101
-
项目类别:
-
资助金额:$13.6万
-
财政年份:2019
-
负责人:Scott Dryden-Peterson
-
依托单位:
A multilevel intervention (Potlako+) to improve timely cancer detection and treatment initiation
-
批准号:10242834
-
项目类别:
-
资助金额:$47.91万
-
财政年份:2019
-
负责人:Scott Dryden-Peterson
-
依托单位:
A multilevel intervention (Potlako+) to improve timely cancer detection and treatment initiation
-
批准号:10478285
-
项目类别:
-
资助金额:$48.07万
-
财政年份:2019
-
负责人:Scott Dryden-Peterson
-
依托单位:
A multilevel intervention (Potlako+) to improve timely cancer detection and treatment initiation
-
批准号:10696252
-
项目类别:
-
资助金额:$46.95万
-
财政年份:2019
-
负责人:Scott Dryden-Peterson
-
依托单位:
Risk factors for early morbidity and mortality of HIV-exposed uninfected infants
-
批准号:8262976
-
项目类别:
-
资助金额:$13.69万
-
财政年份:2012
-
负责人:Scott Dryden-Peterson
-
依托单位:
Risk factors for early morbidity and mortality of HIV-exposed uninfected infants
-
批准号:8868893
-
项目类别:
-
资助金额:$12.85万
-
财政年份:2012
-
负责人:Scott Dryden-Peterson
-
依托单位:
Risk factors for early morbidity and mortality of HIV-exposed uninfected infants
-
批准号:8505366
-
项目类别:
-
资助金额:$13.38万
-
财政年份:2012
-
负责人:Scott Dryden-Peterson
-
依托单位:
Risk factors for early morbidity and mortality of HIV-exposed uninfected infants
-
批准号:8686729
-
项目类别:
-
资助金额:$13.16万
-
财政年份:2012
-
负责人:Scott Dryden-Peterson
-
依托单位:
海外基金